Literature DB >> 12783251

Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy.

Antonio I Picon1, Harvey G Moore, Stephen S Sternberg, Bruce D Minsky, Philip B Paty, David Blumberg, Stuart H Quan, W Douglas Wong, Alfred M Cohen, Jose G Guillem.   

Abstract

BACKGROUND AND AIMS: Although the standard of care for T3 and/or N1-2 rectal cancers includes adjuvant chemoradiation, it is unclear whether T3 N0 patients with limited microscopic perirectal fat invasion warrant further therapy. Our aim was to determine the prognostic significance of gross perirectal fat invasion, or depth of microscopic perirectal fat invasion, in T3 N0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. PATIENTS AND METHODS: Utilizing a prospective database, the medical records of 108 patients who underwent a potentially curative resection for T3 N0 rectal cancer between June 1986 and December 1994 were analyzed. All pathological specimens were re-reviewed by a single pathologist, and extent of perirectal fat invasion was measured in millimeters. Patients who received either preoperative or postoperative adjuvant therapy were excluded.
RESULTS: Macroscopic perirectal fat invasion (T3 gross) was present in 49 cases, absent in 40 cases (T3 microscopic), and not reported in 19 cases. Rectal cancers were stratified by extent of measured perirectal fat invasion into 3 mm or less and more than 3 mm. Five-year overall and local recurrence rates for the entire group were 19% and 8%, respectively. The disease-free survival, disease-specific survival, and overall recurrence for rectal cancers with 3 mm or less invasion vs. more than 3 mm invasion, or T3 gross vs. T3 microscopic, were not statistically different.
CONCLUSION: Our data suggest that the extent of gross, or microscopic perirectal fat invasion (defined as >3 or </=3 mm), determined in the resected specimen, does not predict outcome in select T3 N0 rectal cancers.

Entities:  

Mesh:

Year:  2003        PMID: 12783251     DOI: 10.1007/s00384-003-0504-1

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  26 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Local recurrence following total mesorectal excision for rectal cancer.

Authors:  G Arbman; E Nilsson; O Hallböök; R Sjödahl
Journal:  Br J Surg       Date:  1996-03       Impact factor: 6.939

3.  Long-term functional results of coloanal anastomosis for rectal cancer.

Authors:  P B Paty; W E Enker; A M Cohen; B D Minsky; H Friedlander-Klar
Journal:  Am J Surg       Date:  1994-01       Impact factor: 2.565

4.  The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function.

Authors:  C F Kollmorgen; A P Meagher; B G Wolff; J H Pemberton; J A Martenson; D M Illstrup
Journal:  Ann Surg       Date:  1994-11       Impact factor: 12.969

5.  Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114.

Authors:  J E Tepper; M J O'Connell; G R Petroni; D Hollis; E Cooke; A B Benson; B Cummings; L L Gunderson; J S Macdonald; J A Martenson
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

6.  Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer.

Authors:  S J Cawthorn; D V Parums; N M Gibbs; R P A'Hern; S M Caffarey; C I Broughton; C G Marks
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

7.  Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.

Authors:  N Wolmark; H S Wieand; D M Hyams; L Colangelo; N V Dimitrov; E H Romond; M Wexler; D Prager; A B Cruz; P H Gordon; N J Petrelli; M Deutsch; E Mamounas; D L Wickerham; E R Fisher; H Rockette; B Fisher
Journal:  J Natl Cancer Inst       Date:  2000-03-01       Impact factor: 13.506

8.  Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997.

Authors:  R J Heald; B J Moran; R D Ryall; R Sexton; J K MacFarlane
Journal:  Arch Surg       Date:  1998-08

9.  Total mesorectal excision in the operative treatment of carcinoma of the rectum.

Authors:  W E Enker; H T Thaler; M L Cranor; T Polyak
Journal:  J Am Coll Surg       Date:  1995-10       Impact factor: 6.113

10.  Postoperative adjuvant radiotherapy for adenocarcinoma of the rectum and rectosigmoid.

Authors:  A Vigliotti; T A Rich; M M Romsdahl; H R Withers; M J Oswald
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-07       Impact factor: 7.038

View more
  19 in total

1.  Prognostic relevant factors within pT3 rectal carcinomas: depth of invasion or circumferrential resection margins?

Authors:  Benno Mann
Journal:  Int J Colorectal Dis       Date:  2003-06-03       Impact factor: 2.571

2.  Clinical significance of magnetic resonance imaging findings in rectal cancer.

Authors:  Charles F Bellows; Bernard Jaffe; Lorenzo Bacigalupo; Salvatore Pucciarelli; Guiseppe Gagliardi
Journal:  World J Radiol       Date:  2011-04-28

3.  Preoperative chemoradiotherapy for clinically diagnosed T3N0 rectal cancer.

Authors:  In Ja Park; Jee Yeon Kim; Chang Sik Yu; Jong Seok Lee; Seok-Byung Lim; Jong Lyul Lee; Yong Sik Yoon; Chan Wook Kim; Jin Cheon Kim
Journal:  Surg Today       Date:  2015-02-25       Impact factor: 2.549

4.  Selective use of preoperative chemoradiotherapy for T3 rectal cancer can be justified: analysis of local recurrence.

Authors:  Se-Jin Baek; Seon-Hahn Kim; Jung-Myun Kwak; Jae-Sung Cho; Jae-Won Shin; Azali Hafiz Yafee Amar; Jin Kim
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

5.  Concordance and survival implications of preoperative subclassification of T3 rectal cancers by depth of mesorectal invasion using a 5-mm cut-off point with endorectal ultrasound and magnetic resonance imaging.

Authors:  Stephanie García Botello; Rosa Martí Fernández; Coral Cozar Lozano; Salvador Campos Salher; Jose Martín Arévalo; David Moro Valdezate; Vicente Pla Martí; Alejandro Espí Macías
Journal:  Quant Imaging Med Surg       Date:  2022-04

6.  Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer.

Authors:  Deniz Tural; Fatih Selcukbiricik; Özcan Yıldız; Olgun Elcin; Sibel Erdamar; Sabri Güney; Fuat Demireli; Evin Büyükünal; Süheyla Serdengeçti
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

7.  Depth of tumor invasion in locally advanced rectal cancer correlates with patients' prognosis: the usefulness of elastic stain for its measurement.

Authors:  Daisuke Katsumata; Hirokazu Fukui; Yuko Ono; Kazuhito Ichikawa; Shigeki Tomita; Johji Imura; Akihito Abe; Masanori Fujita; Osamu Watanabe; Masahiro Tsubaki; Masakatsu Sunagawa; Takahiro Fujimori
Journal:  Surg Today       Date:  2008-02-01       Impact factor: 2.549

8.  Prognostic significance of a preoperative magnetic resonance imaging assessment of the distance of mesorectal extension in clinical T3 lower rectal cancer.

Authors:  Toshinori Sueda; Masayuki Ohue; Shingo Noura; Tatsushi Shingai; Katsuyuki Nakanishi; Masahiko Yano
Journal:  Surg Today       Date:  2016-01-14       Impact factor: 2.549

9.  Patterns of care and outcomes for adjuvant treatment of pT3N0 rectal cancer using the National Cancer Database.

Authors:  Thomas J Quinn; Malolan S Rajagopalan; Beant Gill; Shabnam M Mehdiabadi; Peyman Kabolizadeh
Journal:  J Gastrointest Oncol       Date:  2020-02

10.  Benefit of the measurement of mesorectal extension in patients with pT3N1-2 rectal cancer without pre-operative chemoradiotherapy: Post-operative treatment strategy.

Authors:  Yoshito Akagi; Kazuo Shirouzu; Shin Fujita; Hideki Ueno; Yasumasa Takii; Koji Komori; Masaaki Ito; Kenichi Sugihara
Journal:  Exp Ther Med       Date:  2012-12-14       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.